Literature DB >> 30664782

Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques.

Karin Dijkman1, Claudia C Sombroek2, Richard A W Vervenne2, Sam O Hofman2, Charelle Boot2, Edmond J Remarque2, Clemens H M Kocken2, Tom H M Ottenhoff3, Ivanela Kondova2, Mohammed A Khayum2, Krista G Haanstra2, Michel P M Vierboom2, Frank A W Verreck4.   

Abstract

Tuberculosis (TB) remains the deadliest infectious disease1, and the widely used Bacillus Calmette-Guérin (BCG) vaccine fails to curb the epidemic. An improved vaccination strategy could provide a cost-effective intervention to break the transmission cycle and prevent antimicrobial resistance2,3. Limited knowledge of the host responses critically involved in protective immunity hampers the development of improved TB vaccination regimens. Therefore, assessment of new strategies in preclinical models to select the best candidate vaccines before clinical vaccine testing remains indispensable. We have previously established in rhesus macaques (Macaca mulatta) that pulmonary mucosal BCG delivery reduces TB disease where standard intradermal injection fails4,5. Here, we show that pulmonary BCG prevents infection by using a repeated limiting-dose Mycobacterium tuberculosis challenge model and identify polyfunctional T-helper type 17 (TH17) cells, interleukin-10 and immunoglobulin A as correlates of local protective immunity. These findings warrant further research into mucosal immunization strategies and their translation to clinical application to more effectively prevent the spread of TB.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30664782     DOI: 10.1038/s41591-018-0319-9

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  80 in total

1.  Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment.

Authors:  Uma Shanmugasundaram; Allison N Bucsan; Shashank R Ganatra; Chris Ibegbu; Melanie Quezada; Robert V Blair; Xavier Alvarez; Vijayakumar Velu; Deepak Kaushal; Jyothi Rengarajan
Journal:  JCI Insight       Date:  2020-07-23

2.  Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques.

Authors:  Michel P M Vierboom; Agnes L Chenine; Patricia A Darrah; Richard A W Vervenne; Charelle Boot; Sam O Hofman; Claudia C Sombroek; Karin Dijkman; Mohamed A Khayum; Marieke A Stammes; Krista G Haanstra; Chantal Hoffmann; Doris Schmitt; Nathalie Silvestre; Alexander G White; H Jacob Borish; Robert A Seder; Nadia Ouaked; Stephane Leung-Theung-Long; Geneviève Inchauspé; Ravi Anantha; Mary Limbach; Thomas G Evans; Danilo Casimiro; Maria Lempicki; Dominick J Laddy; Aurelio Bonavia; Frank A W Verreck
Journal:  NPJ Vaccines       Date:  2020-05-14       Impact factor: 7.344

Review 3.  Targeting innate immunity for tuberculosis vaccination.

Authors:  Shabaana A Khader; Maziar Divangahi; Willem Hanekom; Philip C Hill; Markus Maeurer; Karen W Makar; Katrin D Mayer-Barber; Musa M Mhlanga; Elisa Nemes; Larry S Schlesinger; Reinout van Crevel; Raman (Krishna) Vankayalapati; Ramnik J Xavier; Mihai G Netea
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

4.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

5.  Tuberculosis vaccine finds an improved route.

Authors:  Samuel M Behar; Chris Sassetti
Journal:  Nature       Date:  2020-01       Impact factor: 49.962

Review 6.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

Review 7.  Moving tuberculosis vaccines from theory to practice.

Authors:  Peter Andersen; Thomas J Scriba
Journal:  Nat Rev Immunol       Date:  2019-09       Impact factor: 53.106

Review 8.  BCG: a vaccine with multiple faces.

Authors:  Marco Antonio Yamazaki-Nakashimada; Alberto Unzueta; Luisa Berenise Gámez-González; Napoleón González-Saldaña; Ricardo U Sorensen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

9.  Targeted Phage Display-based Pulmonary Vaccination in Mice and Non-human Primates.

Authors:  Daniela I Staquicini; E Magda Barbu; Rachel L Zemans; Beth K Dray; Fernanda I Staquicini; Prashant Dogra; Marina Cardó-Vila; Cindy K Miranti; Wallace B Baze; Luisa L Villa; Jorge Kalil; Geetanjali Sharma; Eric R Prossnitz; Zhihui Wang; Vittorio Cristini; Richard L Sidman; Andrew R Berman; Reynold A Panettieri; Rubin M Tuder; Renata Pasqualini; Wadih Arap
Journal:  Med (N Y)       Date:  2020-12-10

Review 10.  The knowns and unknowns of latent Mycobacterium tuberculosis infection.

Authors:  W Henry Boom; Ulrich E Schaible; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.